Neurocrine Biosciences, Inc. (NBIX) Shares Obtained by Van ECK Associates Corp

Neurocrine Biosciences, Inc. (NBIX) Shares Obtained by Van ECK Associates Corp

Van ECK Associates Corp increased its stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 6.0% during the first quarter, Holdings Channel reports. The institutional investor owned 176,376 shares of the company’s stock after buying an additional 10,002 shares during the period. Van ECK Associates Corp’s holdings in Neurocrine Biosciences were worth $7,637,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. Perceptive Advisors LLC bought a new stake in shares of Neurocrine Biosciences during the fourth quarter valued at $128,349,000. BB Biotech AG increased its stake in shares of Neurocrine Biosciences by 1.6% in the first quarter. BB Biotech AG now owns 3,201,552 shares of the company’s stock valued at $138,627,000 after buying an additional 50,000 shares in the last quarter. Franklin Resources Inc. increased its stake in shares of Neurocrine Biosciences by 19.8% in the fourth quarter. Franklin Resources Inc. now owns 2,409,715 shares of the company’s stock valued at $93,256,000 after buying an additional 397,429 shares in the last quarter. Janus Capital Management LLC increased its stake in shares of Neurocrine Biosciences by 10.6% in the fourth quarter. Janus Capital Management LLC now owns 2,356,485 shares of the company’s stock valued at $91,203,000 after buying an additional 224,906 shares in the last quarter. Finally, State Street Corp increased its stake in shares of Neurocrine Biosciences by 6.8% in the fourth quarter. State Street Corp now owns 2,289,171 shares of the company’s stock valued at $88,571,000 after buying an additional 145,703 shares in the last quarter. 97.60% of the stock is currently owned by institutional investors.

Neurocrine Biosciences, Inc. (NBIX) traded up 2.57% during midday trading on Friday, reaching $46.25. The company had a trading volume of 1,398,389 shares. Neurocrine Biosciences, Inc. has a 1-year low of $37.35 and a 1-year high of $55.38. The stock’s market capitalization is $4.07 billion. The firm’s 50 day moving average is $51.82 and its 200 day moving average is $45.53.

Neurocrine Biosciences (NASDAQ:NBIX) last released its quarterly earnings results on Tuesday, May 9th. The company reported ($0.90) EPS for the quarter, missing the consensus estimate of ($0.67) by $0.23. During the same quarter last year, the business posted ($0.22) EPS. On average, equities analysts anticipate that Neurocrine Biosciences, Inc. will post ($2.46) EPS for the current fiscal year.

NBIX has been the topic of several analyst reports. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $80.00 price target on shares of Neurocrine Biosciences in a research report on Tuesday, March 7th. Piper Jaffray Companies reaffirmed an “overweight” rating and set a $96.00 price target on shares of Neurocrine Biosciences in a research report on Friday, February 10th. Oppenheimer Holdings Inc. set a $60.00 price target on Neurocrine Biosciences and gave the stock a “buy” rating in a research report on Saturday, April 8th. Bank of America Corp initiated coverage on Neurocrine Biosciences in a research report on Friday, May 5th. They set a “buy” rating and a $70.00 price target on the stock. Finally, Jefferies Group LLC increased their price target on Neurocrine Biosciences from $59.00 to $65.00 and gave the stock a “buy” rating in a research report on Wednesday, April 12th. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and sixteen have assigned a buy rating to the company’s stock. Neurocrine Biosciences has a consensus rating of “Buy” and a consensus price target of $67.69.

In other news, insider Haig P. Bozigian sold 13,065 shares of the stock in a transaction that occurred on Wednesday, April 12th. The shares were sold at an average price of $50.42, for a total value of $658,737.30. Following the sale, the insider now directly owns 129,805 shares in the company, valued at $6,544,768.10. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Malcolm Lloyd-Smith sold 9,960 shares of the stock in a transaction that occurred on Friday, May 19th. The shares were sold at an average price of $53.63, for a total transaction of $534,154.80. Following the completion of the sale, the insider now owns 17,997 shares in the company, valued at $965,179.11. The disclosure for this sale can be found here. Insiders sold 104,360 shares of company stock worth $5,501,889 over the last quarter. Company insiders own 4.80% of the company’s stock.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “NASDAQ:NBIX”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Want to see what other hedge funds are holding NBIX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Neurocrine Biosciences, Inc. (NASDAQ:NBIX).

Related posts

Leave a Comment